A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Criteria the registry did not label

• 1b / 2a Inclusion Criteria:
• ≥18 years of age
• Histologic documentation of prostate adenocarcinoma
• Metastatic disease, documented by imaging. Imaging performed within 56 days prior to Screening is acceptable
  • 1b / 2a Exclusion Criteria:
• Current or prior evidence of any small cell or neuroendocrine histology on the most recent prostate biopsy.
• Any liver metastases confirmed by biopsy or evidence of lesions \>1 cm consistent with liver metastases on imaging.
• Intervention with any chemotherapy, investigational agent, or other anticancer drug, including enzalutamide, apalutamide, or darolutamide, 14 days prior to Cycle 1 Day 1 or 5 half-lives (whichever is shorter).
• Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the Investigator may interfere with study participation and compliance or place the participant at high risk from treatment-related complications.
  • 2a only -key inclusion criteria:
• Must have received at least 2 cycles of PLUVICTO®
• 1 line of prior any ARPI therapy
• No prior chemotherapy for mCRPC